ImmunityBio Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This ImmunityBio Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
ImmunityBio presents a practical BD-screening case because its returned pipeline contains 59 records and the deal search returned 7 transaction records. The lead returned asset is Nogapendekin alfa inbakicept-pmln, associated with IL-2Rβγ and metastatic non-small cell lung cancer, Carcinoma in Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, at Approved. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Nogapendekin alfa inbakicept-pmln | ImmunityBio, Inc. | Approved | Pipeline record: IL-2Rβγ; metastatic non-small cell lung cancer, Carcinoma in Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch | Approved asset with IL-2Rβγ exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | Intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin(ImmunityBio) | ImmunityBio, Inc. | Phase 2 | Pipeline record: target not returned; Non-Muscle Invasive Bladder Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Biopharma Cigalah to distribute ImmunityBio' ANKTIVA plus Bacillus Calmette-Guerin for BCG-unresponsive NMIBC in Saudi Arabia | Phase 2 asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | CD19.t-haNK(ImmunityBio) | ImmunityBio, Inc. | Phase 2 | Pipeline record: CD19; Refractory Indolent Non-Hodgkin Lymphoma, B-cell lymphoma recurrent, B-cell lymphoma refractory. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | ImmunityBio and NantKwest Complete Merger | Phase 2 asset with CD19 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | Cytokine induced memory like NK cell therapy(ImmunityBio) | ImmunityBio, Inc. | Phase 2 | Pipeline record: target not returned; Refractory acute myeloid leukemia. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch | Phase 2 asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | Memory cytokine-enriched NK cell therapy (ImmunityBio) | ImmunityBio, Inc. | Phase 2 | Pipeline record: target not returned; Adenocarcinoma of prostate, Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Biopharma Cigalah to distribute ImmunityBio' ANKTIVA plus Bacillus Calmette-Guerin for BCG-unresponsive NMIBC in Saudi Arabia | Phase 2 asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2026-02-19 | ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch | Active | disclosed: false |
| 2026-01-14 | Biopharma Cigalah to distribute ImmunityBio' ANKTIVA plus Bacillus Calmette-Guerin for BCG-unresponsive NMIBC in Saudi Arabia | Active | disclosed: false |
| 2020-12-21 | ImmunityBio and NantKwest Complete Merger | Completed | disclosed: false |
The most relevant returned precedent is: ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch (2026-02-19). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- ImmunityBio, Inc. - 2021 Quarterly report: ImmunityBio, Inc. - 2021 Quarterly report Components of our Results of Operations Our principal sources of liquidity are our existing cash, cash equivalents, and marketable securities. We have historically invested our cash primarily in investment grade short- to intermediate-term corporate debt securities, commercial paper, government-sponsored securities, U.S. treasury securities, and foreign government bonds and classify these investments as available-for-sale. Certain of these investments are subject to general credit, liquidity and other market risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets. As of June 30, 2021, we had cash and ca
- ImmunityBio, Inc. - 2023 Quarterly report: ImmunityBio, Inc. - 2023 Quarterly report Financial Condition, Liquidity and Capital Resources Following our BLA resubmission, we continue to explore a strategic partnership for commercialization of N-803 for intravesical administration. There is a risk that our ability to enter into such a strategic partnership transaction may be impacted by the CRL and BLA resubmission and associated review process. Further, there are other factors that may impact our ability, or decision, to enter into such a strategic partnership, and ultimately there can be no assurance that we will complete a transaction on acceptable terms in accordance with our anticipated timeline, or at all. If we do not execute a strategic partnership transaction in the near-term, it would eliminate a potential source of near-te
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether ImmunityBio is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
ImmunityBio merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate Nogapendekin alfa inbakicept-pmln, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
